Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity

Ping Lun Jiang, Hung Jun Lin, Hsiao Wen Wang, Wen Yu Tsai, Shen Fu Lin, Mei Yin Chien, Pi Hui Liang, Yi You Huang, Der Zen Liu

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens and mount protective immunity. We previously demonstrated that intranasal administration of targeted galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that mediated by unmodified liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced higher levels of pro-inflammatory cytokines than unmodified liposomes in vitro. C57BL/6 mice thrice immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high levels of OVA-specific IgG antibodies in their serum. Spleen cells from mice receiving galactosylated liposomes were restimulated with OVA and showed significantly augmented levels of IFN-γ, IL-4, IL-5 and IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indicate that nasal administration of a galactosylated liposome vaccine mediates the development of an effective immunity against tumors and might be useful for further clinical anti-tumoral applications.

Original languageEnglish
Pages (from-to)356-367
Number of pages12
JournalActa Biomaterialia
Volume11
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Vaccines
Liposomes
Dendritic Cells
Tumors
Immunity
Ovalbumin
Neoplasms
Intranasal Administration
Antibodies
Inbred C57BL Mouse
Antibody Formation
Interleukin-5
Pathogens
Antigens
Interleukin-4
Interleukin-6
Spleen
Immunoglobulin G
Cytokines

Keywords

  • Antigen delivery
  • Cancer immunotherapy
  • Dendritic cell targeted
  • Galactosylated liposome
  • Mucosal vaccine

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Medicine(all)

Cite this

Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity. / Jiang, Ping Lun; Lin, Hung Jun; Wang, Hsiao Wen; Tsai, Wen Yu; Lin, Shen Fu; Chien, Mei Yin; Liang, Pi Hui; Huang, Yi You; Liu, Der Zen.

In: Acta Biomaterialia, Vol. 11, No. 1, 2015, p. 356-367.

Research output: Contribution to journalArticle

Jiang, Ping Lun ; Lin, Hung Jun ; Wang, Hsiao Wen ; Tsai, Wen Yu ; Lin, Shen Fu ; Chien, Mei Yin ; Liang, Pi Hui ; Huang, Yi You ; Liu, Der Zen. / Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity. In: Acta Biomaterialia. 2015 ; Vol. 11, No. 1. pp. 356-367.
@article{e09ba35e2fae48bca641a081fb96b55d,
title = "Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity",
abstract = "Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens and mount protective immunity. We previously demonstrated that intranasal administration of targeted galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that mediated by unmodified liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced higher levels of pro-inflammatory cytokines than unmodified liposomes in vitro. C57BL/6 mice thrice immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high levels of OVA-specific IgG antibodies in their serum. Spleen cells from mice receiving galactosylated liposomes were restimulated with OVA and showed significantly augmented levels of IFN-γ, IL-4, IL-5 and IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indicate that nasal administration of a galactosylated liposome vaccine mediates the development of an effective immunity against tumors and might be useful for further clinical anti-tumoral applications.",
keywords = "Antigen delivery, Cancer immunotherapy, Dendritic cell targeted, Galactosylated liposome, Mucosal vaccine",
author = "Jiang, {Ping Lun} and Lin, {Hung Jun} and Wang, {Hsiao Wen} and Tsai, {Wen Yu} and Lin, {Shen Fu} and Chien, {Mei Yin} and Liang, {Pi Hui} and Huang, {Yi You} and Liu, {Der Zen}",
year = "2015",
doi = "10.1016/j.actbio.2014.09.019",
language = "English",
volume = "11",
pages = "356--367",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity

AU - Jiang, Ping Lun

AU - Lin, Hung Jun

AU - Wang, Hsiao Wen

AU - Tsai, Wen Yu

AU - Lin, Shen Fu

AU - Chien, Mei Yin

AU - Liang, Pi Hui

AU - Huang, Yi You

AU - Liu, Der Zen

PY - 2015

Y1 - 2015

N2 - Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens and mount protective immunity. We previously demonstrated that intranasal administration of targeted galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that mediated by unmodified liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced higher levels of pro-inflammatory cytokines than unmodified liposomes in vitro. C57BL/6 mice thrice immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high levels of OVA-specific IgG antibodies in their serum. Spleen cells from mice receiving galactosylated liposomes were restimulated with OVA and showed significantly augmented levels of IFN-γ, IL-4, IL-5 and IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indicate that nasal administration of a galactosylated liposome vaccine mediates the development of an effective immunity against tumors and might be useful for further clinical anti-tumoral applications.

AB - Mucosal surfaces contain specialized dendritic cells (DCs) that are able to recognize foreign pathogens and mount protective immunity. We previously demonstrated that intranasal administration of targeted galactosylated liposomes can elicit mucosal and systemic antibody responses. In the present study, we assessed whether galactosylated liposomes could act as an effective DC-targeted mucosal vaccine that would be capable of inducing systemic anti-tumor immunity as well as antibody responses. We show that targeted galactosylated liposomes effectively facilitated antigen uptake by DCs beyond that mediated by unmodified liposomes both in vitro and in vivo. Targeted galactosylated liposomes induced higher levels of pro-inflammatory cytokines than unmodified liposomes in vitro. C57BL/6 mice thrice immunized intranasally with ovalbumin (OVA)-encapsulated galactosylated liposomes produced high levels of OVA-specific IgG antibodies in their serum. Spleen cells from mice receiving galactosylated liposomes were restimulated with OVA and showed significantly augmented levels of IFN-γ, IL-4, IL-5 and IL-6. In addition, intranasal administration of OVA-encapsulated beta-galactosylated liposomes resulted in complete protection against EG7 tumor challenge in C57BL/6 mice. Taken together, these results indicate that nasal administration of a galactosylated liposome vaccine mediates the development of an effective immunity against tumors and might be useful for further clinical anti-tumoral applications.

KW - Antigen delivery

KW - Cancer immunotherapy

KW - Dendritic cell targeted

KW - Galactosylated liposome

KW - Mucosal vaccine

UR - http://www.scopus.com/inward/record.url?scp=84924990125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924990125&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2014.09.019

DO - 10.1016/j.actbio.2014.09.019

M3 - Article

C2 - 25242652

AN - SCOPUS:84924990125

VL - 11

SP - 356

EP - 367

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 1

ER -